Carl Zeiss Meditec AG (XSWX:AFX) Total Equity: CHF1,952 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
78 GF Score
Price CHF28.46
GF Value CHF71.65
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Total Equity?

Carl Zeiss Meditec AG XSWX:AFX -2.60% 78 Total Equity is CHF1,952 Mil as of Mar. 2026. GuruFocus rates XSWX:AFX with a GF Score™ of 78/100 and a GF Value™ of CHF71.65. The stock has 4 warning signs investors should review.

Carl Zeiss Meditec AG's total equity for the quarter that ended in Mar. 2026 was CHF1,952 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Carl Zeiss Meditec AG Total Equity Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Total Equity Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,813.46 1,957.46 2,104.55 1,936.06 1,989.16

Carl Zeiss Meditec AG Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,049.86 1,936.06 1,997.41 1,989.16 1,951.76
XSWX:AFX
78GF Score
Carl Zeiss Meditec AG XSWX:AFX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Carl Zeiss Meditec AG's Total Equity for the fiscal year that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=3234.1887326338-1245.0268741475
=1,989

Carl Zeiss Meditec AG's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3090.9818129952-1139.2189948917
=1,952

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF1,952 Mil mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Total Equity of CHF1,952 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Total Equity too high?
Carl Zeiss Meditec AG's current Total Equity is CHF1,952 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Total Equity compare to ISRG and BDX?
Carl Zeiss Meditec AG's Total Equity of CHF1,952 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Total Equity is CHF1,952 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XSWX:AFX) has a current Total Equity of CHF1,952 Mil. The stock's GF Value™ is CHF71.65, compared to a current price of CHF28.46 — trading 60.3% below its estimated fair value. The current Total Equity is CHF1,952 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Total Equity is CHF1,952 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF28.46 is trading 60.3% below its estimated GF Value™ of CHF71.65.

Key valuation signals for XSWX:AFX:

  • Total Equity: CHF1,952 Mil
  • GF Value™: CHF71.65 vs. price of CHF28.46 (60.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
78GF Score

Get the complete analysis for XSWX:AFX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF28.46
Price
CHF71.65
GF Value